Approach to Rash in a Patient with HIV

More documents

Recommendations

Info

Sulfa RashIn: HIV and AIDS. Polsky & Clumeck(Eds). 1999Khambahty, M.M. & Hsu, S.S. Emerg Med Clin North Am 2010; 28:355• Peak time 1-313 wk afterstarting sulfa; months oryears later possible• Usually mild/modseverity; hyper-sensitivity syndrome orSJS/TEN possible• Desensitization formild/mod rash an option• Possible X-reactivity XwithfAPV, , DRV, & dapsone
PhotodermatitisMaurer, TA. Topics HIV Med. 2005;13(5). http://www.iasusa.org/pub/topics/2005/issue5/149.pdf•Photosensitizing drugTMP/SMX•Limited to sun-exposed areas•People of color at higher risk
Page 1 and 2: Approach to Rash in aPatient with H
Page 3 and 4: Discussion Topics• Causes & types
Page 5 and 6: Case 1• Put on Epzicom (abacavir/
Page 7 and 8: Skin Disorders Commonin HIV + Perso
Page 9 and 10: Cutaneous Drug Reactions:What Type
Page 11 and 12: Cutaneous Drug Reaction:Moderate Se
Page 13 and 14: Severe/Life-ThreateingCutaneous Dru
Page 15 and 16: Case 1 - Continued• Patient repor
Page 17 and 18: ARV drugs frequentlyassociated with
Page 19 and 20: Abacavir HSRFrom FDA-approved packa
Page 21 and 22: Abacavir HSR• Most signs/symptoms
Page 23: Darunavir• Rash, ~7%.• Most mil
Page 27 and 28: Eosinophilic FolliculitisMaurer TA
Page 29 and 30: Rashes Caused byInfections
Page 31 and 32: Secondary Syphilis
Page 33 and 34: Varicella-Zoster Virus (VZV)HIV Web
Page 35 and 36: What would be an appropriatenext st
Page 37 and 38: Cutaneous Drug Reaction:Patient Cou
Page 39 and 40: What do you recommend aboutfuture u
Page 41 and 42: What would be theappropriate next s
Page 43 and 44: Approach to EfavirenzRash• Usuall
Page 45 and 46: What would be theappropriate next s
Page 47 and 48: Patient BF
Page 49 and 50: Case 3: Continued• Seen by primar
Page 51 and 52: Patient BF’s Diagnosis:Neurosyphi
Page 53: Nevirapine Rash• More common in w

Approach to Rash in a Patient with HIV

Create successful ePaper yourself

Delete template?

Save as template?